Evaluation of Global Post-Outbreak COVID-19 Treatment Interventions: A Systematic Review and Bibliometric Analysis of Randomized Controlled Trials

References

• Benita F. Human mobility behavior in COVID-19: a systematic literature review and bibliometric analysis. Sustain Cities Soc. 2021;70:102916. doi:10.1016/J.SCS.2021.102916
   PubMed Web of Science ®Google Scholar
• Utami AM, Rendrayani F, Khoiry QA, et al. Economic evaluation of COVID-19 vaccination: a systematic review. J Glob Health. 2023;13:6001. doi:10.7189/JOGH.13.06001
   Web of Science ®Google Scholar
• Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection. 2020;48(2):155–163. doi:10.1007/S15010-020-01401-Y/TABLES/3
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMOA2002032/SUPPL_FILE/NEJMOA2002032_DISCLOSURES.PDF
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Coronavirus (COVID-19) dashboard with vaccination data; 2023. Available from: https://covid19.who.int/. Accessed September 10, 2023.
   Google Scholar
• Ang L, Song E, Lee MS. Randomized controlled trials of traditional, complementary, and integrative medicine-based interventions for coronavirus disease 2019 (COVID-19): a bibliometric analysis and review of study designs. Integr Med Res. 2021;10:100777. doi:10.1016/J.IMR.2021.100777
   PubMed Web of Science ®Google Scholar
• Qomara WF, Primanissa DN, Amalia SH, Purwadi FV, Zakiyah N. Effectiveness of remdesivir, lopinavir/ritonavir, and favipiravir for COVID-19 treatment: a systematic review. Int J Gen Med. 2021;14:8557–8571. doi:10.2147/IJGM.S332458
   PubMed Web of Science ®Google Scholar
• Lou Y, Liu L, Yao H, et al. clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. Eur J Pharm Sci. 2021:157. doi:10.1016/J.EJPS.2020.105631
   Web of Science ®Google Scholar
• Hariton E, Locascio JJ. Randomised controlled trials—the gold standard for effectiveness research. BJOG. 2018;125(13):1716. doi:10.1111/1471-0528.15199
   PubMed Web of Science ®Google Scholar
• Fragkou PC, Belhadi D, Peiffer-Smadja N, et al. Review of trials currently testing treatment and prevention of COVID-19. Clin Microbiol Infect. 2020;26(8):988–998. doi:10.1016/J.CMI.2020.05.019
   PubMed Web of Science ®Google Scholar
• Murakami N, Hayden R, Hills T, et al. Therapeutic advances in COVID-19. Nat Rev Nephrol. 2022;19(1):38–52. doi:10.1038/s41581-022-00642-4
   PubMed Web of Science ®Google Scholar
• Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615. doi:10.1038/s41591-021-01283-z
   PubMed Web of Science ®Google Scholar
• Karampitsakos T, Papaioannou O, Tsiri P, et al. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial. Clin Microbiol Infect. 2023;29(3):372–378. doi:10.1016/J.CMI.2022.10.015
   PubMed Web of Science ®Google Scholar
• Karampitsakos T, Sotiropoulou V, Katsaras M, et al. Post-COVID-19 interstitial lung disease: insights from a machine learning radiographic model. Front Med Lausanne. 2023:9. doi:10.3389/fmed.2022.1083264
   Web of Science ®Google Scholar
• World Health Organization. COVID-19 studies from the world health organization database; 2023. Available from: https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov. Accessed September 10, 2023.
   Google Scholar
• ClinicalTrials.gov. COVID-19 studies from ClinicalTrials.gov Database; 2023. Available from: https://clinicaltrials.gov/. Accessed September 10, 2023.
   Google Scholar
• Carley S, Horner D, Body R, MacKway-Jones K. Evidence-based medicine and COVID-19: what to believe and when to change. Emer Med J. 2020;37(9):572–575. doi:10.1136/EMERMED-2020-210098
   PubMed Web of Science ®Google Scholar
• Siemieniuk RAC, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020:370. doi:10.1136/BMJ.M2980
   Google Scholar
• Hernandez AV, Roman YM, Pasupuleti V, Barboza JJ, White CM. Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review. Ann Intern Med. 2020;173(4):287–297. doi:10.7326/M20-2496/SUPPL_FILE/M20-2496_SUPPLEMENT.PDF
   PubMed Web of Science ®Google Scholar
• Kudhail K, Thompson J, Mathews V, Morrison B, Hemming K. Randomized controlled trials in patients with COVID-19: a systematic review and critical appraisal. Inter J Infect Dis. 2022;122:72–80. doi:10.1016/j.ijid.2022.05.034
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/BMJ.N71
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• Risk of bias tools. Current version of RoB 2; 2019. Available from: https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/current-version-of-rob-2?authuser=0. Accessed September 13, 2023.
   Google Scholar
• Ding Y, Chowdhury GG, Foo S. Bibliometric cartography of information retrieval research by using co-word analysis. Inf Process Manag. 2001;37(6):817–842. doi:10.1016/S0306-4573(00)00051-0
   Web of Science ®Google Scholar
• van Eck NJ, Waltman L. Software survey: vOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–538. doi:10.1007/s11192-009-0146-3
   PubMed Web of Science ®Google Scholar
• VOSviewer. Visualizing scientific landscapes; 2023. Available from: https://www.vosviewer.com/. Accessed September 13, 2023.
   Google Scholar
• Tableau. Tableau Desktop 8.1.10; 2023. Available from: https://www.tableau.com/support/releases/desktop/8.1.10. Accessed September 13, 2023.
   Google Scholar
• Dalavi AM, Gomes A, Javed Husain A. Bibliometric analysis of nature inspired optimization techniques. Comput Ind Eng. 2022;169:108161. doi:10.1016/J.CIE.2022.108161
   Web of Science ®Google Scholar
• McGuinness LA, Higgins JP. T. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55–61. doi:10.1002/jrsm.1411
   PubMed Web of Science ®Google Scholar
• Rabie ASI, Salah H, Said ASA, et al. Clinical consequences for individuals treated with tocilizumab for serious COVID-19 Infection. Healthcare. 2023;11(4). doi:10.3390/healthcare11040607
   Web of Science ®Google Scholar
• Baldeón ME, Maldonado A, Ochoa-Andrade M, et al. Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection. Transfus Med. 2022;32(2):153–161. doi:10.1111/tme.12851
   PubMed Web of Science ®Google Scholar
• Muralidharan J, Kashyap S, P S, et al. The effect of L-arginine supplementation on amelioration of oxygen support in severe COVID-19 pneumonia. Clin Nutr ESPEN. 2022;52:431–435. doi:10.1016/j.clnesp.2022.09.024
   PubMedGoogle Scholar
• Liu ST, Zhan C, Ma YJ, et al. Effect of qigong exercise and acupressure rehabilitation program on pulmonary function and respiratory symptoms in patients hospitalized with severe COVID-19: a randomized controlled trial. Integr Med Res. 2021:10. doi:10.1016/j.imr.2021.100796
   Web of Science ®Google Scholar
• Srivastava A, Rengaraju M, Srivastava S, et al. Efficacy of two siddha polyherbal decoctions, Nilavembu Kudineer and Kaba Sura Kudineer, along with standard allopathy treatment in the management of mild to moderate symptomatic COVID-19 patients—a double-blind, placebo-controlled, clinical trial. Trials. 2021;22(1). doi:10.1186/s13063-021-05478-0
   Web of Science ®Google Scholar
• Panatto D, Orsi A, Bruzzone B, et al. Efficacy of the sentinox spray in reducing viral load in mild COVID-19 and its virucidal activity against other respiratory viruses: results of a randomized controlled trial and an in vitro study. Viruses. 2022;14(5):1033. doi:10.3390/v14051033
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu L, Xu X, et al. Effectiveness of lianhua qingwen capsule in treatment of asymptomatic COVID-19 patients: a randomized, controlled multicenter trial. J Complement Integr Med. 2022;28(11):887–894. doi:10.1089/jicm.2021.0352
   Google Scholar
• Koshak AE, Koshak EA, Mobeireek AF, et al. Nigella sativa for the treatment of COVID-19: an open-label randomized controlled clinical trial. Complement Ther Med. 2021:61. doi:10.1016/j.ctim.2021.102769
   Google Scholar
• Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181(1):24–31. doi:10.1001/jamainternmed.2020.6615
   PubMed Web of Science ®Google Scholar
• Kumari P, Dembra S, Dembra P, et al. The role of vitamin c as adjuvant therapy in COVID-19. Cureus. 2020. doi:10.7759/cureus.11779
   Web of Science ®Google Scholar
• Chowdhury AT, Shahbaz M, Karim MR, Islam J, Dan G, He S. A comparative study on ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID-19 patients. Eurasian J Med Oncol. 2021;5(1):63–70. doi:10.14744/ejmo.2021.16263
   Google Scholar
• Welzel T, Atkinson A, Schöbi N, et al. Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): an open-label, multicentre, randomised trial. Lancet Child Adolesc Health. 2023;7(4):238–248. doi:10.1016/S2352-4642(23)00020-2
   PubMedGoogle Scholar
• Rodrigues C, Freitas-Santos RS, Levi JE, et al. Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. Int J Antimicrob Agents. 2021;58(5):106428. doi:10.1016/j.ijantimicag.2021.106428
   PubMed Web of Science ®Google Scholar
• Ranjbar K, Moghadami M, Mirahmadizadeh A, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021;21(1). doi:10.1186/s12879-021-06045-3
   Web of Science ®Google Scholar
• Heydari M, Rahimi J, Foroozanfar Z, et al. The efficacy of ivermectin and metronidazole vs. standard treatment protocols on outcomes of COVID-19 in hospitalized patients: a triple-blinded randomized controlled trial. Arch Clin Infect Dis. 2022;17(5). doi:10.5812/archcid-122525
   Web of Science ®Google Scholar
• Schwartz IS, Boulware DR, Lee TC. Hydroxychloroquine for COVID19: the curtains close on a comedy of errors. Lancet Regional Health. 2022;11. doi:10.1016/j.lana.2022.100268
   Google Scholar
• Chen CP, Lin YC, Chen TC, et al. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS One. 2020;15(12 December). doi:10.1371/journal.pone.0242763
   Web of Science ®Google Scholar
• Nojomi M, Yassin Z, Keyvani H, et al. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis. 2020;20(1). doi:10.1186/s12879-020-05698-w
   PubMed Web of Science ®Google Scholar
• Kamran SM, Moeed HA, Mirza Z, et al. Clearing the fog: is hydroxychloroquine effective in reducing coronavirus disease-2019 progression? A randomized controlled trial. Cureus. 2021;30. doi:10.7759/cureus.14186
   Google Scholar
• Annweiler C, Beaudenon M, Gautier J, et al. High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): a multicenter, open-label, randomized controlled superiority trial. PLoS Med. 2022;19(5):e1003999. doi:10.1371/journal.pmed.1003999
   PubMed Web of Science ®Google Scholar
• Golan Y, Campos JAS, Woolson R, et al. Favipiravir in patients with early mild-to-moderate coronavirus disease 2019 (COVID-19): a randomized controlled trial. Clin Infect Dis. 2023;76(3):E10–E17. doi:10.1093/cid/ciac712
   PubMed Web of Science ®Google Scholar
• Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ. 2022;194(7):E242–E251. doi:10.1503/CMAJ.211698
   PubMed Web of Science ®Google Scholar
• Avezum Á, Oliveira GBF, Oliveira H, et al. Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE – coalition V): a double-blind, multicentre, randomised, controlled trial. Lancet Regional Health. 2022;11:100243. doi:10.1016/j.lana.2022.100243
   Google Scholar
• Xie Y, Zhang P, Zhao H, Suyun L, Li J. Analysis of clinical research characteristics of clinical study on coronavirus disease 2019: based on inter- national clinical trial registration platform. J Traditional Chin Med. 2020. doi:10.13288/J.11-2166
   Google Scholar
• London AJ, Kimmelman J. Against pandemic research exceptionalism. Science. 2020;368(6490):476–477. doi:10.1126/SCIENCE.ABC1731/ASSET/590F0371-2E1E-417F-BC49-828C4D4D4DF7/ASSETS/GRAPHIC/368_476_F1.JPEG
   PubMed Web of Science ®Google Scholar
• Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med. 2020;383(21):2030–2040. doi:10.1056/NEJMOA2022926/SUPPL_FILE/NEJMOA2022926_DATA-SHARING.PDF
   PubMed Web of Science ®Google Scholar
• Saag MS. Misguided use of hydroxychloroquine for COVID-19: the infusion of politics into science. JAMA. 2020;324(21):2161–2162. doi:10.1001/JAMA.2020.22389
   PubMed Web of Science ®Google Scholar
• Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013:346. doi:10.1136/BMJ.E7586
   Google Scholar
• Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340(7748):698–702. doi:10.1136/BMJ.C332
   Google Scholar
• Li J, Hu JY, Zhai JB, et al. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM): recommendations, explanation and elaboration. Complement Ther Med. 2019;46:180–188. doi:10.1016/J.CTIM.2019.08.014
   PubMed Web of Science ®Google Scholar
• Olivo SA, Macedo LG, Gadotti IC, Fuentes J, Stanton T, Magee DJ. Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther. 2008;88(2):156–175. doi:10.2522/PTJ.20070147
   PubMed Web of Science ®Google Scholar
• Freiman JA, Chalmers TC, Smith HA, Kuebler RR. The importance of beta, the type II error, and sample size in the design and interpretation of the randomized controlled trial: survey of two sets of “negative” trials. Medical Uses Statistics. 2019;357–389. doi:10.1201/9780429187445-19
   Google Scholar
• Moher D, Wells GA, Dulberg CS. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA. 1994;272(2):122–124. doi:10.1001/JAMA.1994.03520020048013
   PubMed Web of Science ®Google Scholar
• Zhu RF, Gao YL, Robert SH, et al. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19). J Transl Med. 2020;18(1):274. doi:10.1186/s12967-020-02442-5
   PubMed Web of Science ®Google Scholar
• Mubaroq SR, Abdullah AG, Setiawan A. The evolution of smart working and sustainability in socio-technical perspective: a scientometrics technology analysis. J Eng Sci Technol. 2020;15:1868–1882.
   Web of Science ®Google Scholar
• CNN. Covid-19 vaccine trial on humans starts as UK warns restrictions could stay in place until next year | CNN; 2020. Available from: https://edition.cnn.com/2020/04/23/health/coronavirus-vaccine-trial-uk-gbr-intl/index.html. Accessed September 20, 2023.
   Google Scholar
• Tran BX, Ha GH, Nguyen LH, et al. Studies of novel coronavirus disease 19 (COVID-19) pandemic: a global analysis of literature. Int J Environ Res Public Health. 2020;17(11):4095. doi:10.3390/ijerph17114095
   PubMed Web of Science ®Google Scholar
• Zhao MZ, Zhao C, Tu S, Wei XX, Shang HC. Evaluating the methodology of studies conducted during the global COVID-19 pandemic: a systematic review of randomized controlled trials. J Integr Med. 2021;19(4):317–326. doi:10.1016/J.JOIM.2021.03.003
   PubMedGoogle Scholar
• Zuidgeest MGP, Goetz I, Groenwold RH, Irving E, van Thiel GJ, Grobbee DE. Series: pragmatic trials and real world evidence: paper 1. Introduction. J Clin Epidemiol. 2017;88:7–13. doi:10.1016/J.JCLINEPI.2016.12.023
   PubMed Web of Science ®Google Scholar
• Head BW. Reconsidering evidence-based policy: key issues and challenges. Policy Soc. 2010;29(2):77–94. doi:10.1016/J.POLSOC.2010.03.001
   Web of Science ®Google Scholar
• Alexander PE, Debono VB, Mammen MJ, et al. COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. J Clin Epidemiol. 2020;123:120–126. doi:10.1016/J.JCLINEPI.2020.04.016
   PubMed Web of Science ®Google Scholar
• Hiebert R, Nordin M. Methodological aspects of outcomes research. Eur Spine J. 2006;15(Suppl 1):S4. doi:10.1007/S00586-005-1057-5
   PubMedGoogle Scholar
• Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007;10(5):326–335. doi:10.1111/J.1524-4733.2007.00186.X
   PubMed Web of Science ®Google Scholar
• Porat T, Nyrup R, Calvo RA, Paudyal P, Ford E. Public health and risk communication during COVID-19-enhancing psychological needs to promote sustainable behaviour change In review Conflict of interest statement; 2020. Available from: www.frontiersin.org. Accessed September 30, 2023.
   Google Scholar